發(fā)布時間：2018-08-08 16:52

【摘要】：目的觀察冠心丹參滴丸治療慢性穩(wěn)定型心絞痛血瘀證患者臨床療效。方法采取隨機、雙盲、安慰劑對照的方法將240例慢性穩(wěn)定型心絞痛血瘀證患者分為治療組與對照組各120例。治療組在西藥常規(guī)治療基礎(chǔ)上給予冠心丹參滴丸口服,對照組在西藥常規(guī)治療基礎(chǔ)上給予安慰劑口服,均每次0.4 g,每日3次,連續(xù)1個月。觀察治療前后患者的中醫(yī)主癥計分、血瘀證計分及血清可溶性細胞間黏附分子1(s ICAM-1)、可溶性血管細胞間黏附分子1(s VCAM-1)水平變化,并觀察不良反應。結(jié)果治療組納入統(tǒng)計108例,對照組納入統(tǒng)計104例。兩組患者治療后中醫(yī)主癥計分、血瘀證計分、血清s VCAM-1及s ICAM-1水平均較治療前明顯降低(P0.05);治療組治療后血瘀證計分、血清s VCAM-1及s ICAM-1水平治療后均較對照降低明顯(P0.05)。治療期間兩組均未出現(xiàn)嚴重的不良反應。結(jié)論冠心丹參滴丸可有效的降低慢性穩(wěn)定型心絞痛血瘀證患者血瘀證計分及血清s ICAM-1、s VCAM-1水平。
[Abstract]:Objective to observe the clinical effect of Guanxin Danshen dropping pill on chronic stable angina pectoris with blood stasis syndrome. Methods 240 patients with chronic stable angina pectoris and blood stasis syndrome were randomly divided into treatment group (n = 120) and control group (n = 120). The treatment group was treated with Guanxin Danshen dropping pills on the basis of routine western medicine, while the control group was given placebo on the basis of routine western medicine treatment, three times a day for 1 month. The scores of main symptoms, blood stasis syndrome, serum soluble intercellular adhesion molecule 1 (s ICAM-1) and soluble vascular intercellular adhesion molecule 1 (s VCAM-1) were observed before and after treatment, and adverse reactions were observed. Results 108 cases were included in the treatment group and 104 cases in the control group. After treatment, the scores of TCM main symptoms, blood stasis syndrome, serum s VCAM-1 and s ICAM-1 in the two groups were significantly lower than those before treatment (P0.05); after treatment, the scores of blood stasis syndrome, serum s VCAM-1 and s ICAM-1 in the treatment group were significantly lower than those in the control group (P0.05). There were no serious adverse reactions in both groups during the treatment. Conclusion Guanxin Danshen dropping pills can effectively reduce the score of blood stasis syndrome and the level of serum sICAM-1s VCAM-1 in patients with chronic stable angina pectoris with blood stasis syndrome.
【作者單位】： 中國中醫(yī)科學院西苑醫(yī)院;北京中醫(yī)藥大學;
【基金】：國家科技重大專項(2009ZX09502-031)
【分類號】：R259

【參考文獻】

相關(guān)期刊論文 前10條

1 楊巧寧;谷豐;高鑄燁;張慶翔;時莉曉;李立志;史大卓;;冠心丹參滴丸治療冠心病隨機對照試驗的系統(tǒng)評價[J];中國實驗方劑學雜志;2014年16期

2 張琳琳;狄長華;陳風;;冠心丹參滴丸對冠心病心絞痛患者血清C反應蛋白及基質(zhì)金屬蛋白酶-9的影響[J];實用臨床醫(yī)藥雜志;2013年15期

3 李艷;劉衛(wèi)星;;血漿sICAM-1、sVCAM-1含量與冠心病氣虛血瘀證的相關(guān)性研究[J];山東中醫(yī)藥大學學報;2012年06期

4 付長庚;高鑄燁;王培利;王承龍;徐浩;史大卓;陳可冀;;冠心病血瘀證診斷標準研究[J];中國中西醫(yī)結(jié)合雜志;2012年09期

5 張青;;冠心丹參滴丸治療冠心病心絞痛療效觀察[J];中外醫(yī)療;2012年15期

6 楊寶元;李繼安;董印宏;馮偉;張磊;;冠心病氣虛血瘀證血管內(nèi)皮細胞功能失調(diào)相關(guān)性研究[J];江蘇中醫(yī)藥;2011年08期

7 譚R，

本文編號：2172415